Gary Nachman

Gary Nachman joined Raymond James in 2023 as a senior analyst covering biotechnology and specialty pharmaceuticals. Prior to joining the firm, he was most recently a managing director covering biopharma and specialty pharma at BMO Capital Markets for seven years. Before that, he was a senior analyst covering specialty pharma at Goldman Sachs, Susquehanna International Group, Leerink Swann and Morgan Stanley. Before getting into equity research, Gary spent a few years in the pharmaceutical industry at Merck, where he was a manager in the financial evaluations group at Merck‐Medco. Gary earned his MBA from Columbia Business School and a B.S. in accounting from Binghamton University, where he graduated magna cum laude.